Drug acetylation in liver disease

Clinical Pharmacokinetics

Volumn 34, Issue 3, 1998, Pages 219-226

  Levy, Micha ^a   Caraco, Yoseph ^a   Geisslinger, Gerd ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE;

ACETYLATOR PHENOTYPE; CHRONIC LIVER DISEASE; DRUG ACETYLATION; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; PRIORITY JOURNAL; REVIEW;

ACETYLATION; ACETYLTRANSFERASES; ACUTE DISEASE; ARYLAMINE N-ACETYLTRANSFERASE; CHRONIC DISEASE; HUMANS; ISOENZYMES; LIVER DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 0031890139     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834030-00004     Document Type: Review

References (42)

1. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79
2. Cribb AE, Nakamura H, Grant DM, et al. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol 1993; 45: 1277-82
3. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferase. Pharmacogenetics 1995; 5: 1-17
4. Grant DM, Houghes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376; 61-70
5. Perry Jr HM, Tan EM, Carmody S, et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970; 76: 114-25
6. Lunde PKM, Frislid K, Haustein V. Disease and acetylation polymorphism. Clin Pharmacokinet 1977; 2: 182-97
7. Woosley RL, Drayer DE, Reidenberg MM, et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157-9
8. O'Neil WM, Gilfix BM, DiGirolamo A, et al. N-Acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow?. Clin Pharmacol Ther 1997; 62: 261-71
9. Shear NA, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-89
10. Buhl R, Jaffe HA, Holroyd KY, et al. Systemic glutathione deficiency in symptom-free HIV-sero-positive individuals. Lancet 1989; II: 1294-8
11. Ellard GA, Gammon PT. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulfadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol 1977; 4: 5-14
12. Ratain MJ, Mick R, Berezin F, et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991; 50: 573-9
13. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Acta Biochem Biophys 1988; 948: 37-66
14. Roots I, Drakoulis N, Brockmoller J. Polymorphic enzymes and cancer risk. Concepts, methodology and data review. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergmon Press, 1992: 815-41
15. Yu MC, Skipper PL, Taghizadeh K, et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in White. Black and Asian men in Los Angeles, California. J Natl Can Inst 1994; 86: 712-6
16. Feng Y, Rustan TD, Ferguson RJ, et al. Acetylator genotype-dependent formation of 2-aminofluorene-hemoglobin adducts in rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol Appl Pharmacol 1994; 124: 10-5
17. Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994; 369: 154-6
18. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 alloenzymes: effect of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55: 3531-6
19. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42-69
20. Hoyumpa A, Schenker S. Is glucuronidation truly preserved in patients with liver disease. Hepatology 1991; 13: 786-95
21. Desmond PV, Smyth FE, Mashford ML. Release of latent glucuronosyltransferase activity contributes to the sparing of glucuronidation in experimental liver injuries. J Gastroenterol Hepatol 1994; 9: 350-4
22. Held H, Fried F. Elimination of para-aminosalicylic acid in patients with liver disease and renal insufficiency. Chemotherapy 1977; 23: 405-15
23. Souich P, Erill S. Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease. Clin Pharmacol Ther 1977; 22: 588-95
24. Pacifici GM, Viani A, Franchi M, et al. Conjugation pathways in liver disease. Br J Clin Pharmacol 1990; 30: 427-35
25. Dowling TC, Frye RF, Matzke GR, et al. Reduced acetylation of PAH in liver disease [abstract]. Clin Pharmacol Ther 1997; 61: 215
26. Horvath T, Par A, Past T, et al. Disorders of biotransformation during the progression of alcoholic liver disease. Acta Physiol Hung 1986; 4: 351-7
27. Horvath T, Past T, Nemeth A, et al. Drug metabolism in drug induced liver diseases: pathogenetic role of active metabolites. Acta Physiol Hung 1989; 73: 293-304
28. Ahmad R, Al-Taee M. The effect of acute viral hepatitis on the activity of N-acetyltransferase. Int Hepatol Commun 1995; 3: 123-5
29. Horvath T, Past T, Tatai Z, et al. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials. Pol J Pharmacol Pharm 1984; 36: 361-71
30. Timbrell JA, Wright JM. Urinary metabolic profile of isoniazid in patients who develop isoniazid-related liver damage. Human Toxicol 1984; 3: 485-95
31. Levi AJ, Sherlock S, Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968; 1: 1275-9
32. Accocella G, Bonollo L, Garimoldi M, et al. Kinetics of rifampin and isomazid administrated alone and in combination to normal subjects and patients with liver disease. Gut 1972; 13: 47-53
33. Filho RAP, Seva-Pereira A, de Magalhaes AFN, et al. A acetilacao da isoniazida na cirrose hepatica. Rev Paul Med 1985; 103: 276-9
34. Levy M, Leibowitz Y, Zylber-Katz E, et al. Impairment of dipyrone's metabolism in asymptomatic carriers of hepatitis B virus. Clin Pharmacol Ther 1997; 62: 6-14
35. Zylber-Katz E, Caraco Y, Granit L, et al. Dipyrone metabolism in liver disease. Clin Pharmacol Ther 1995; 58: 198-209
36. May DG, Arns PA, Richard WO, et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992; 51: 689-700
37. Rodopoulos N, Wisen O, Norman A. Caffeine metabolism in patients with chronic liver disease. Scand J Lab Invest 1995; 55: 229-42
38. Denaro CP, Wilson M, Jacob P, et al. The effect of liver disease on urine caffeine metabolic ratios. Clin Pharmacol Ther 1996; 59: 624-35
39. El-Yazigi A, Raines DA, Abdel Wahab F, et al. Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases. J Clin Pharmacol 1995; 35: 615-21
40. Irshaid YM, Al-Hadid HF, Abuirjeie MA, et al. N-acetylation phenotyping using dapsone in a Jordanian population. Br J Clin Pharmacol 1991; 32: 289-93
41. Horai Y, Ishizaki T. N-acetylation polymorphism of dapsone in Japanese population. Br J Clin Pharmacol 1988; 25: 487-94
42. Tang BK, Kadar D, Qian L, et al. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991; 49: 648-57